Last reviewed · How we verify
Vonoprazan+amoxicillin+tetracycline 14 days
This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously attacking the bacteria with two antibiotics (amoxicillin and tetracycline).
This triple-drug combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously attacking the bacteria with two antibiotics (amoxicillin and tetracycline). Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | Vonoprazan+amoxicillin+tetracycline 14 days |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Combination therapy: potassium-competitive acid blocker + beta-lactam antibiotic + tetracycline antibiotic |
| Target | H+ K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (tetracycline) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the proton pump to reduce gastric acid, creating an environment where amoxicillin and tetracycline can effectively penetrate and kill H. pylori. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis, while tetracycline inhibits bacterial protein synthesis. The combination is administered for 14 days as a standard triple-therapy regimen for H. pylori eradication.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Photosensitivity (tetracycline-related)
- Allergic reaction (amoxicillin-related)
Key clinical trials
- Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
- Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial (PHASE4)
- Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy (PHASE4)
- Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication (PHASE4)
- Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori (NA)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
- Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication (PHASE4)
- The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |